Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Ginkgo Bioworks Inc.

    NYSE: DNA · Real-Time Price · USD
    11.27
    1.81 (19.13%)
    At close: Jun 30, 2025, 3:59 PM
    11.25
    -0.17%
    After-hours: Jun 30, 2025, 06:02 PM EDT
    19.13%
    Bid 11.25
    Market Cap 659.65M
    Revenue (ttm) 237.42M
    Net Income (ttm) -472.07M
    EPS (ttm) -8.91
    PE Ratio (ttm) -1.26
    Forward PE -2.36
    Analyst Sell
    Ask 11.3
    Volume 2,596,112
    Avg. Volume (20D) 1,313,093
    Open 9.77
    Previous Close 9.46
    Day's Range 9.67 - 11.50
    52-Week Range 5.00 - 16.85
    Beta 1.26

    About DNA

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol DNA
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for DNA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Ginkgo Bioworks Inc. is scheduled to release its earnings on Aug 7, 2025, after market closes.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    +14.73%
    Ginkgo Bioworks shares are trading higher after th... Unlock content with Pro Subscription
    2 months ago
    +11.23%
    Shares of healthcare technology stocks are trading higher. Some stocks in the sector rose after the FDA stated plans to phase out animal testing requirements for monoclonal antibodies and other drugs.
    news image

    1 day ago · accessnewswire.com

    Applied DNA Sharpens Strategic Focus on Synthetic DNA Manufacturing for Biotherapeutics Applications, Consolidates Operations Behind LineaRx

    - Conducts 27% Workforce Reduction, Ceases Operations at Applied DNA Clinical Labs, Positions LineaRx for Growth - STONY BROOK, NY / ACCESS Newswire / June 30, 2025 / Applied DNA Sciences, Inc. (NASDA...

    news image

    1 week ago · accessnewswire.com

    Silver Scott Health, Inc. to Offer DNA Vibe's Award-Winning Patented Light Therapy Devices

    Division of Silver Scott Mines, Inc. Expands Health and Wellness Offerings FRANKLIN, NJ / ACCESS Newswire / June 24, 2025 / Silver Scott Health, Inc., a division of Silver Scott Mines, Inc. (OTC PINK:...

    news image

    2 weeks ago · accessnewswire.com

    Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward

    President and COO Judy Murrah Appointed New Chairperson of the Board of Directors and CEO STONY BROOK, NY / ACCESS Newswire / June 17, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or...

    news image

    2 weeks ago · accessnewswire.com

    Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3'25 Financial Results Report in Mid-August

    STONY BROOK, NY / ACCESS Newswire / June 16, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it will resu...

    news image

    2 weeks ago · nypost.com

    23andMe's founder Anne Wojcicki wins bid for bankrupt DNA testing firm

    23andMe filed for bankruptcy in March, seeking to sell its business at auction after a decline in consumer demand and a 2023 data breachthat exposed sensitive genetic and personal information of milli...

    news image

    2 weeks ago · reuters.com

    23andMe's founder Anne Wojcicki wins bid for DNA testing firm

    Anne Wojcicki is set to regain control of 23andMe after a nonprofit she controls topped Regeneron's bid for the DNA-testing company.

    news image

    3 weeks ago · accessnewswire.com

    Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome

    Treatment restored gene control, extended telomere length beyond healthy levels, reversed muscle and weight loss, reduced oxidative stress, and resulted in 100% survival - highlighting Telomir-1's pot...

    news image

    1 month ago · accessnewswire.com

    Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025

    STONY BROOK, NY / ACCESS Newswire / May 29, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it will effec...

    news image

    1 month ago · businesswire.com

    Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

    SAN DIEGO--(BUSINESS WIRE)--Telesis Bio Inc. (OTCMKTS: TBIO), a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundr...

    news image

    1 month ago · businessinsider.com

    23andMe was once worth $6 billion. What's left of the DNA testing startup is being bought for $256 million.

    Regeneron Pharmaceuticals will acquire 23andMe's assets for $256 million, both companies said. 23andMe filed for Chapter 11 bankruptcy earlier this year.

    Add to Watchlist